Answers are grounded in this paper and cite their sources.
These data demonstrate the prophylactic and therapeutic efficacy of this new class of human monoclonal antibodies in a highly stringent and clinically relevant animal model of influenza and justify clinical development of this approach as intervention for both seasonal and pandemic influenza.
No takes yet. Share an insight, caveat, or question.
Friesen et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: